SCP 26
July 3 to July 6, 2017 WIPO’s Page for the Meeting SCP26 – Agreement reached on future work reached at WIPO Standing Committee on the Law of Patents (6 July 2017) WIPO SCP 26 KEI Side Event: Running royalties as… Continue Reading
Intellectual Property Rights
Compulsory licensing as a limitation on the remedies for infringement in medical technology cases in the US
The following are cases in the United States wherein compulsory licensing as a limitation on the remedies for infringement (Trips Article 44 cases) relating to medical technologies. 2012: Conceptus, Inc. v. Hologic, Inc. Conceptus, inc. filed a patent infringement case… Continue Reading
Statutory authority for non-voluntary use of patented inventions in United States
(More on compulsory licensing here.) This is a non-exhaustive set of provisions in US statutes that are used to for non-voluntary use of patented inventions. 28 U.S.C. 1498 – Patent and copyright cases (a) Whenever an invention described in and… Continue Reading
Compulsory licensing
Global norms on compulsory licensing Country experiences Compulsory licensing in the United States Statutory authority for compulsory licenses on patents in the United States Compulsory licensing as a remedy to anticompetitive practices Compulsory licensing under the Bayh-Dole Act Compulsory licensing… Continue Reading
WIPO’s Standing Committee on the Law of Patents (SCP)
World Intellectual Property Organization (WIPO)
KEI has permanent observer status for the World Intellectual Property Organization (WIPO), and has attended every SCCR meeting beginning in 2003, and monitors several other committees. KEI played a key role in the negotiations on the Marrakesh treaty for persons… Continue Reading
KEI Work on CRISPR and CRISPR-related Inventions
You also can search for our most recent work on clustered regularly interspaced short palindromic repeats (CRISPR) technologies using our tags here, or via our general search engine here. KEI Events regarding CRISPR 2019: Expert Workshop at Brocher Foundation- An… Continue Reading
KEI Publications
KEI publishes research and commentary in a variety of journals, periodicals, books and other independent publishing platforms. In-house, KEI presents information in blogs, correspondence and reports, as well as in occasional KEI research notes and papers. Timelines (several) Timelines regarding… Continue Reading
KEI comments at July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation
These are the notes I used when providing the KEI comments at the July 25, 2017 civil society stakeholder forum at the 19th round of the RCEP negotiation.
My name is James Love. I work for Knowledge Ecology International, an NGO that focuses on the social aspects to the production, management and control of knowledge goods. I am also a member of the board of directors of the Union for Affordable Cancer Treatment.
The IP Chapter is complex, and in the time allocated, I will discuss five issues.
German Federal Supreme Court Affirms Compulsory License on HIV Drug
On July 11, 2017, the German Federal Supreme Court announced that it had affirmed the decision of the Federal Patent Court last year to issue a compulsory license allowing Merck to continue selling its HIV drug, raltegravir (marketed as Isentress).